Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 8월 28

Ardent Health Inc

ARDTNYSE
Trade with Public
Trade with Public
$10.99
-0.24-2.14%
가까이에: Aug 26, 5:00 PM EST
$11.13
-0.1-0.89%
프리마켓: 7:22 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Ardent Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ardent Health (ARDT).

Price Target Range — 9 Quarters

Analyst Consensus — 12 Analysts

9Buy
2Hold
1Sell
Consensus RatingBuy# Analysts12Avg. Consensus PT$16Upside to Avg. PT+43.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 10, 2026RBC CapitalBen HendrixPT RaiseOutperform$12→$13
Aug 6, 2026Truist SecuritiesDavid MacdonaldPT RaiseBuy$12→$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and lowers the price target from $13 to $12.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and lowers the price target from $13 to $12.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Ardent Health, Raises Price Target to $13.5

UBS analyst A.J. Rice maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $13.5.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved